172 related articles for article (PubMed ID: 24358271)
1. A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A.
Tatsumi K; Sugimoto M; Lillicrap D; Shima M; Ohashi K; Okano T; Matsui H
PLoS One; 2013; 8(12):e83280. PubMed ID: 24358271
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
3. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
7. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
8. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
10. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
[TBL] [Abstract][Full Text] [Related]
12. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.
Kren BT; Unger GM; Sjeklocha L; Trossen AA; Korman V; Diethelm-Okita BM; Reding MT; Steer CJ
J Clin Invest; 2009 Jul; 119(7):2086-99. PubMed ID: 19509468
[TBL] [Abstract][Full Text] [Related]
13. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
[TBL] [Abstract][Full Text] [Related]
14. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
15. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.
Liu L; Mah C; Fletcher BS
Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640
[TBL] [Abstract][Full Text] [Related]
16. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
Moayeri M; Hawley TS; Hawley RG
Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
[TBL] [Abstract][Full Text] [Related]
17. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
19. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
[TBL] [Abstract][Full Text] [Related]
20. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]